 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Linezolid works largely by stopping bacteria from multiplying rather than by killing them. It is also effective in treating certain types of infections due to bacteria known as enterococci that have become resistant to all previously available antibiotics. Linezolid does not damage kidney or liver function. Even though this is a new drug, there is evidence that a few bacteria have already developed resistance, a problem that has been observed most often in seriously ill patients who have dialysis catheters or other prosthetic devices in place. Linezolid can cause high blood pressure when taken in conjunction with common cold remedies that contain phenylpropanolamine or pseudoephedrine. It has also occasionally caused bone marrow suppression (a decrease in the production of new blood cells), although this adverse effect appears to go away once use of the drug is stopped.
SUMMARIES FOR PATIENTS
Linezolid
21 January 2003 | Volume 138 Issue 2 | Page I-44
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Linezolid: The First Oxazolidinone Antimicrobial." It is in the 21 January 2003 issue of Annals of Internal Medicine (volume 138, pages 135-142). The author is RC Moellering Jr.
What is the problem and what is known about it so far?
Antibiotics are drugs used to treat bacterial infections. These drugs have been responsible for saving millions of lives over the years. Partially because they are so useful, doctors have tended to overuse them, and this has allowed bacteria to adjust to their presence, becoming resistant to their bacteria-killing effects. As a result of the development of antibiotic resistance, certain types of bacteria have become extremely difficult to treat since few (or no) antibiotics remain effective against them. For this reason, it has become critically important to develop new drugs that can treat these difficult infections.
Why did the author do this review?
To inform the medical community about the development and effectiveness of a new drug, linezolid, which is used to treat several serious antibiotic-resistant infections.
How did the author do this review?
The author reviewed numerous studies conducted on the use of linezolid in treating infectious disease.
What did the author find?
Linezolid is one member of a new class of antibiotics. Linezolid is effective against almost all bacteria of a common type, known as gram-positive organisms, that includes Staphylococcus (staph) and Streptococcus (strep). The term gram-positive refers to a staining process (named after its developer) that is used to distinguish between two types of bacteria. Gram-positive bacteria cause infections acquired in community settings and hospitals.
What are the implications of this review?
Linezolid is an important addition to the antibiotic options available for treating certain drug-resistant bacteria. Patients with underlying conditions that could lead to bone marrow suppression must be carefully monitored during the course of treatment. This new drug should not be overused, or its effectiveness will also probably be diminished by the emergence of resistant strains of bacteria.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J Elvy, I Hanspal, and P Simcock A case of Erysipelothrix rhusiopathiae causing bilateral endogenous endophthalmitis J. Clin. Pathol., November 1, 2008; 61(11): 1223 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-S. Huang, Y.-C. Liu, C.-L. Sy, Y.-S. Chen, H.-Z. Tu, and B.-C. Chen In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis Complex Isolated in Taiwan over 10 Years Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2226 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Moellering Jr A 39-Year-Old Man With a Skin Infection JAMA, January 2, 2008; 299(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. de Jesus Valle, N. S. Uranga, F. G. Lopez, A. D.-G. Hurle, and A. S. Navarro Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery J. Antimicrob. Chemother., November 1, 2007; 60(5): 1074 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients Drug Metab. Dispos., October 1, 2007; 35(10): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moreillon, W. R. Wilson, R. Leclercq, and J. M. Entenza Single-Dose Oral Amoxicillin or Linezolid for Prophylaxis of Experimental Endocarditis Due to Vancomycin-Susceptible and Vancomycin-Resistant Enterococcus faecalis Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1661 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fiaccadori, U. Maggiore, C. Rotelli, R. Giacosa, E. Parenti, E. Picetti, P. Manini, R. Andreoli, and A. Cabassi Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1402 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Sola, J. M. Bostwick, D. A. Hart, and T. W. Lineberry Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise Mayo Clin. Proc., March 1, 2006; 81(3): 330 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5024 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Debellis, O. P. Schaefer, M. Liquori, and G. A. Volturo Linezolid-Associated Serotonin Syndrome After Concomitant Treatment With Citalopram and Mirtazepine in a Critically Ill Bone Marrow Transplant Recipient J Intensive Care Med, December 1, 2005; 20(6): 303 - 305. [Abstract] [PDF]
|
|
|
|
|
|
P. Beringer, M. Nguyen, N. Hoem, S. Louie, M. Gill, M. Gurevitch, and A. Wong-Beringer Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3676 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Nagiec, L. Wu, S. M. Swaney, J. G. Chosay, D. E. Ross, J. K. Brieland, and K. L. Leach Oxazolidinones Inhibit Cellular Proliferation via Inhibition of Mitochondrial Protein Synthesis Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3896 - 3902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Ziglam, I. Elliott, V. Wilson, K. Hill, and D. Nathwani Clinical audit of linezolid use in a large teaching hospital J. Antimicrob. Chemother., August 1, 2005; 56(2): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schriever, L. Zeitz-Colaizzi, A. Quinn, A. E. Schriever, and J. P. Cannon Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit Journal of Pharmacy Practice, April 1, 2005; 18(2): 100 - 108. [Abstract] [PDF]
|
|
|
|
|
|
C.-H. Liao, S.-P. Tseng, C.-T. Fang, L.-J. Teng, and P.-R. Hsueh First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan J. Antimicrob. Chemother., April 1, 2005; 55(4): 598 - 599. [Full Text] [PDF]
|
|
|
|
 |
|
 G. E Stein, S. L Schooley, C. A Peloquin, V. Kak, D. H Havlichek, D. M Citron, K. L Tyrrell, and E. J. Goldstein Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis Ann. Pharmacother., March 1, 2005; 39(3): 427 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Spellberg, T. Yoo, and A. S. Bayer Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6 J. Antimicrob. Chemother., October 1, 2004; 54(4): 832 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Jones, E. Athan, and D. O'Brien Serotonin syndrome due to co-administration of linezolid and venlafaxine J. Antimicrob. Chemother., July 1, 2004; 54(1): 289 - 290. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Dominguez, J. F. Marcinak, R. S. Daum, E. L. Goodman, H. R. Chang, and M. N. Swartz Cellulitis N. Engl. J. Med., June 10, 2004; 350(24): 2522 - 2524. [Full Text] [PDF]
|
|
|
|
|
|
J. Parra-Ruiz, M. Martinez, R. Antelo-Lorenzo, and J. Hernandez-Quero Antimicrobials in the treatment of orthopaedic prosthetic infections J. Antimicrob. Chemother., May 1, 2004; 53(5): 886 - 887. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Dibo, S. K. Pillai, H. S. Gold, M. R. Baer, M. Wetzler, J. L. Slack, P. A. Hazamy, D. Ball, C. B. Hsiao, P. L. McCarthy Jr., et al. Linezolid-Resistant Enterococcus faecalis Isolated from a Cord Blood Transplant Recipient J. Clin. Microbiol., April 1, 2004; 42(4): 1843 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Movahed, B. Kasravi, and C. S. Bryan Prophylactic Use of Vancomycin in Adult Cardiology and Cardiac Surgery Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 13 - 20. [Abstract] [PDF]
|
|
|
|
|
|
E. G. Vazquez, J. Mensa, Y. Lopez, P. D. Couchard, D. Soy, J. R. Fontenla, M. Sarasa, X. Carne, and E. Montull Penetration of Linezolid into the Anterior Chamber (Aqueous Humor) of the Human Eye after Intravenous Administration Antimicrob. Agents Chemother., February 1, 2004; 48(2): 670 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N Serio Acute Delirium Associated with Combined Diphenhydramine and Linezolid Use Ann. Pharmacother., January 1, 2004; 38(1): 62 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Johnson Linezolid: The First Oxazolidinone Antimicrobial Ann Intern Med, November 18, 2003; 139(10): 863 - 863. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lindley Linezolid: The First Oxazolidinone Antimicrobial Ann Intern Med, November 18, 2003; 139(10): 863 - 863. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Paterson, A. W. Pasculle, and K. McCurry Linezolid: The First Oxazolidinone Antimicrobial Ann Intern Med, November 18, 2003; 139(10): 863 - 864. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
